Ligand id: 10067

Name: AFM13

Immunopharmacology Comments
AFM13 actively recruits NK cells (by binding CD16A on their surface) selectively to Hodgkin's lymphoma cells (by binding CD30 on these cancer cells) to destroy the cancer cells [1]. AFM13 is a Phase 2 clinical immuno-oncology candidate.
Immunopharmacology Disease
Disease X-Refs Comment References
Lymphoma, Hodgkin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
Phase 2 clinical candidate for relapsed/refractory Hodgkin lymphoma- see NCT02321592